Selagine has signed a research, development and sublicense agreement with Grifols for the development and commercialisation of immunoglobulin eye drops for dry eye disease.
/PRNewswire/ Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,.